By consolidating their operations, the management teams of both companies expect to gain an even stronger position among the world leaders in animal health.

"The decision behind this project was made with both our hearts and minds. We share the same business philosophy, one which will allow us to grow faster together," saidMarc Prikazsky, President & CEO of Ceva.

Ceva is theninth largest global veterinary health group, focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, ruminants, pigs and poultry. Ceva is directly present in 43 countries and has active business in more than 110.

Sogeval, is thefifth largest French animal health company, specializing in the development, manufacture and marketing of veterinary drugs and speciality products. The firm has been growing steadily and now plays a major role in the prevention and treatment of diseases in both companion animals and livestock. The company operates internationally through three subsidiaries (USA, UK and Denmark) and a network of over 60 distributors worldwide.

"We are looking forward to a partnership based on obvious synergies: for Sogeval this alliance would create the opportunity to accelerate our development by rolling out our expertise globally," saidJosé Daoudal, Sogeval CEO.

The companies share strong similarities in their animal health expertise and corporate culture.

Strong complementary business focus

In the Companion Animal sector,Ceva and Sogeval have developed similar expertise in the areas of cardiology and pain management, that will allow them to consolidate their positions. Each has developed specific complementary therapeutic categories for dogs and cats:

• Sogeval - Antibiotic treatment and dermatology.
• Ceva - Anti-parasitics and behaviour.

In the livestock sector, Ceva and Sogeval both have expertise in the development and formulation of antibiotic, as well as a strong portfolio of vaccines and products for the management and control of reproduction.

Beyond these synergies at a product level, there are also geographical factors that make the two companies a perfect match. The strength of Sogeval in France and that of Ceva internationally will be decisive in strengthening their respective positions in both the domestic and international markets.

Opportunities for specialization in non-pharmaceutical livestock business

The development of biosecurity and nutritionals will continue to be managed by Sofiprotéol, for which this is a strategic priority. The proposed alliance with Ceva will give this activity the benefit of an international partner.

Shared corporate values

Going beyond business expertise, the two companies share very similar values:  innovation, entrepreneurial spirit and solidarity between individuals.

#   #   #

About Ceva: Ceva Santé Animale is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, swine and poultry. The company had sales of more than €608M in 2012 and employs 3,000+ people worldwide. Its headquarters are in Libourne, France. 

About Sogeval: French veterinary pharmaceutical company based in Laval, a Sofiprotéol subsidiary founded in 1978. Sogeval develops, manufactures and markets veterinary drugs and speciality products, under its own brand and for third-party companies. Located in the heart of Europe’s largest agrifood region, Sogeval has experienced continuous growth and now plays a major role in the prevention and treatment of animal diseases. Sogeval today employs 291 people including 236 in France. The CEO of Sogeval is José Daoudal.

Press contacts

Ceva Santé Animale:  
Martin Mitchell, Group Communications Director
Tel. +33 (0)5 57  55 40 80
E-mail: martin.mitchell@ceva.com

 

Sogeval: 
Florence Mourot, Head of Corporate and Internal Communication
Tel: +33 (0)2 43 49 51 51
E-mail: florence.mourot@sogeval.fr